Added by PPMD on February 20, 2013 at 12:00pm — No Comments
The Muscular Dystrophy Association, Parent Project Muscular Dystrophy and the Foundation to Eradicate Duchenne have called on the U.S. Senate and the U.S. House of Representatives to reauthorize the MD CARE Act of 2001, and to continue federal support for the accelerated pace of research and treatment development for muscular dystrophy. We are urging the public to contact their U.S. Senators and ask them to vote for reauthorization of …Continue
Added by PPMD on February 19, 2013 at 10:30am — No Comments
Summit recently announced the formation of an Advisory Board to support the scientific and clinical development of its utrophin modulator program for the treatment of Duchenne.
The Board brings together six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly Duchenne.
Added by PPMD on February 14, 2013 at 10:00am — No Comments
Parent Project Muscular Dystrophy (PPMD) announced that it has funded $59,000 to Krista Vandenborne, PhD of the University of Florida in Gainesville to test the ability of magnetic resonance imaging (MRI) to detect changes in the muscles of those living with …Continue
Added by PPMD on February 4, 2013 at 8:30am — No Comments
Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD).
The European Medicines Agency (EMA) assigned orphan drug status to Prosensa’s two preclinical compounds PRO052 and PRO055 and the US Food and…Continue
Added by PPMD on February 1, 2013 at 12:16pm — No Comments